Company Overview

GSK plc is a global biopharmaceutical company focused on the research, development, manufacturing, and commercialization of prescription medicines and vaccines. The company operates primarily in the pharmaceuticals and vaccines industries, serving governments, healthcare providers, and patients worldwide. GSK’s core revenue drivers are specialty medicines, general medicines, and preventive vaccines addressing infectious diseases and chronic conditions.

The company is positioned around science-led innovation with a strategic emphasis on immunology, oncology, HIV, and infectious diseases. GSK traces its roots back more than 300 years through predecessor companies in the UK pharmaceutical and chemical sectors. In its modern form, GSK was created in 2000 through the merger of Glaxo Wellcome and SmithKline Beecham. A major recent evolution occurred in 2022, when GSK demerged its consumer healthcare business, Haleon, to focus exclusively on biopharmaceuticals.

Business Operations

GSK organizes its operations into two primary business segments: Specialty Medicines and Vaccines, with General Medicines reported as part of pharmaceuticals. Specialty Medicines includes treatments in HIV, oncology, and immunology, with HIV therapies—largely developed through its majority-owned subsidiary ViiV Healthcare—representing a significant portion of revenue. General Medicines encompasses respiratory, anti-infectives, and other established therapies.

The Vaccines segment develops and supplies vaccines for infectious diseases such as shingles, influenza, meningitis, and RSV, serving both pediatric and adult populations. GSK operates globally with integrated R&D, manufacturing, and commercial infrastructure, and maintains long-term partnerships, including its collaboration with Pfizer in ViiV Healthcare, as well as multiple academic and biotech research alliances.

Strategic Position & Investments

GSK’s strategy centers on prioritizing higher-growth, science-driven therapeutic areas while improving R&D productivity and capital discipline. The company has increased investment in oncology and immunology pipelines and advanced the use of platform technologies such as human genetics, functional genomics, and precision medicine to improve drug discovery and success rates.

Notable recent acquisitions and investments include Affinivax, strengthening vaccine development capabilities, and Sierra Oncology, expanding GSK’s oncology portfolio, particularly in hematologic malignancies. GSK continues to invest in mRNA, cell therapy, and next-generation vaccines while selectively divesting non-core assets to redeploy capital into late-stage pipeline programs.

Geographic Footprint

GSK is headquartered in London, United Kingdom, and operates across North America, Europe, Asia-Pacific, Latin America, and Africa. The company generates a substantial share of revenue from the United States, its largest single market, followed by major European countries and Japan.

Manufacturing, R&D, and commercial operations are distributed globally, with significant research centers in the United Kingdom, the United States, Belgium, and Italy. GSK also maintains an extensive presence in emerging markets, supplying vaccines and essential medicines through government tenders and global health organizations.

Leadership & Governance

GSK is governed by a unitary board structure and emphasizes science-led decision-making, responsible capital allocation, and long-term value creation. The leadership team articulates a strategy focused on patient impact, pipeline quality, and operational execution following the consumer healthcare separation.

Key executives include:

• Emma Walmsley – Chief Executive Officer
• Julie Brown – Chief Financial Officer
• Tony Wood – Chief Scientific Officer
• Brian McNamara – Chief Executive Officer, Vaccines
• Luke Miels – Chief Commercial Officer

The leadership philosophy emphasizes accountability, innovation grounded in human biology, and a simplified operating model aligned with GSK’s biopharmaceutical focus.